论文部分内容阅读
目的探讨细胞间黏附分子-1(ICAM-1)在先天性血管瘤患儿长脉宽1064nm Nd:YAG激光干预前后表达变化的临床意义。方法采用ELISA及免疫组化方法测定50例先天性血管瘤患儿激光治疗前及治疗1个月后血清与血管瘤组织中ICAM-1的水平及健康对照组患儿血清和皮肤组织中的ICAM-1水平,将先天性血管瘤患儿术前分别与健康体检者,激光干预后sICAM-1及mICAM-1的表达水平进行比较。结果激光干预前先天性血管瘤患儿血清sICAM-1的水平(566.92±51.39)μg/L明显高于健康对照组(218.01±38.43)μg/L,差异有统计学意义(P<0.01);干预后1个月sICAM-1水平(418.40±55.89)μg/L较干预前有显著下降,差异有统计学意义(P<0.01)。干预前血管瘤组织中mICAM-1显著高于干预后及正常皮肤组织,干预后1个月mICAM-1表达较干预前明显减弱,差异均有统计学意义(P均<0.01)。结论 ICAM-1可能是先天性血管瘤分期诊断和疗效观察的一个临床生物检测指标,进一步的研究有助于婴幼儿先天性血管瘤的诊断和治疗。
Objective To investigate the clinical significance of intercellular adhesion molecule-1 (ICAM-1) expression in long-pulse 1064nm Nd: YAG laser in children with congenital hemangiomas. Methods The levels of ICAM-1 in serum and hemangiomas of 50 children with congenital hemangioma before laser irradiation and one month after treatment were measured by ELISA and immunohistochemistry. The levels of ICAM-1 in serum and skin tissue of children with healthy controls -1 levels in children with congenital hemangioma before surgery, respectively, and healthy subjects, laser interference sICAM-1 and mICAM-1 expression levels were compared. Results The level of sICAM - 1 in children with congenital hemangiomas before laser intervention was significantly higher than that in healthy controls (566.92 ± 51.39 μg / L, 218.01 ± 38.43 μg / L, P <0.01). One month after intervention, the level of sICAM-1 (418.40 ± 55.89) μg / L was significantly lower than that before intervention (P <0.01). The level of mICAM-1 in hemangioma tissues before intervention was significantly higher than that in the normal skin tissues after intervention. The expression of mICAM-1 in the hemangiomas was significantly decreased at 1 month after intervention (P <0.01). Conclusion ICAM-1 may be a clinical biomarker for the staging diagnosis and treatment of congenital hemangioma. Further research is helpful for the diagnosis and treatment of congenital hemangioma in infants.